Mode
Text Size
Log in / Sign up
N/A N=881 Randomized Double-blind Treatment

Efficacy of a Web-based Sexual Violence Risk Reduction Program for Female College Students

Sexual Violence

Enrolled (actual)
881
Serious AEs
Results posted
Feb 2023
Primary outcome: Primary: Change From Baseline in Sexual Violence Victimization at 6-months Follow-up — 5.64; 5.68; 5.52; 8.15 score on a scale — p=.0002

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
RealConsent (Behavioral); Stress and Mood Management (Behavioral)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Georgia State University
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Sexual Violence Victimization at 6-months Follow-up
5.64; 5.68; 5.52; 8.15; 3.69; 3.78 .0002 sig
SECONDARY
Change From Baseline in Alcohol Protective Behaviors at 6 Months
53.53; 53.97; 56.8; 55.0 .03 sig
SECONDARY
Change From Baseline in Dating Risk Behaviors at 6-months Follow-up
35.16; 35.08; 36.2; 36.1 <.05 sig
SECONDARY
Change From Baseline in "Number of Times Engaged in Binge Drinking" to 6-months
1.71; 1.25; 1.11; 1.05 .02 sig
SECONDARY
Change From Baseline in "Average Number of Alcoholic Drinks Per Occasion in Last 30 Days" to 6-months
1.64; 1.45; 1.4; 1.3 .43
SECONDARY
Change From Baseline in Bystander Behavior at 6-months
7.14; 6.58; 6.03; 7.6 .006 sig

Summary

This study evaluates the efficacy of a web-based program for female college freshmen ("RealConsent") in reducing their risk of sexual violence victimization. Half the participants will receive RealConsent-F and half will receive an attention-placebo control ("Stress and Mood Management").

Eligibility Criteria

Inclusion Criteria

  • female, aged 18-20 years, full-time freshmen, matriculated at Georgia State University, Emory University, or University of Georgia, and single (i.e., not in a committed dating relationship).

Exclusion Criteria

  • other education levels, married, and/or graduate status
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03726437). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search